Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2007 1
2008 5
2009 8
2010 9
2011 4
2012 4
2013 5
2014 5
2015 3
2016 3
2017 6
2018 2
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Results by year
Filters applied: . Clear all
Page 1
Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects.
Goldenberg DM, Morschhauser F, Wegener WA. Goldenberg DM, et al. Leuk Lymphoma. 2010 May;51(5):747-55. doi: 10.3109/10428191003672123. Leuk Lymphoma. 2010. PMID: 20214444 Review.
In addition, very low doses of veltuzumab, given either intravenously or subcutaneously, depleted B cells in normal cynomolgus monkeys, and controlled tumor growth in mice bearing human lymphomas. Clinically, veltuzumab has been studied in > 150 patients with lym …
In addition, very low doses of veltuzumab, given either intravenously or subcutaneously, depleted B cells in normal cynomolgus monkey …
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.
Salles G, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, Wenger M, Maloney DG. Salles G, et al. Adv Ther. 2017 Oct;34(10):2232-2273. doi: 10.1007/s12325-017-0612-x. Epub 2017 Oct 5. Adv Ther. 2017. PMID: 28983798 Free PMC article. Review.
Although the proven clinical efficacy and success of rituximab has led to the development of other anti-CD20 monoclonal antibodies in recent years (e.g., obinutuzumab, ofatumumab, veltuzumab, and ocrelizumab), rituximab is likely to maintain a position within the therapeut …
Although the proven clinical efficacy and success of rituximab has led to the development of other anti-CD20 monoclonal antibodies in recent …
Treatment Update of Autoimmune Blistering Diseases.
Kridin K, Ahn C, Huang WC, Ansari A, Sami N. Kridin K, et al. Dermatol Clin. 2019 Apr;37(2):215-228. doi: 10.1016/j.det.2018.12.003. Epub 2019 Feb 14. Dermatol Clin. 2019. PMID: 30850044 Review.
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
Baker KF, Isaacs JD. Baker KF, et al. Ann Rheum Dis. 2018 Feb;77(2):175-187. doi: 10.1136/annrheumdis-2017-211555. Epub 2017 Aug 1. Ann Rheum Dis. 2018. PMID: 28765121 Review.
We summarise the development and recent application of Janus kinase (JAK) inhibitors in the treatment of IMIDs, including first-generation pan-JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib) and second-generation selective JAK inhibitors (decernotinib, filgoti …
We summarise the development and recent application of Janus kinase (JAK) inhibitors in the treatment of IMIDs, including first-generation p …
Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris.
Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM, Payne AS. Ellebrecht CT, et al. JAMA Dermatol. 2014 Dec;150(12):1331-5. doi: 10.1001/jamadermatol.2014.1939. JAMA Dermatol. 2014. PMID: 25133328 Free PMC article.
Relapse and response to veltuzumab generally correlated with desmoglein 3 enzyme-linked immunosorbent assay index values. ...Clinical trials of subcutaneous veltuzumab for PV are warranted....
Relapse and response to veltuzumab generally correlated with desmoglein 3 enzyme-linked immunosorbent assay index values. ...Clinical …
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment.
Du FH, Mills EA, Mao-Draayer Y. Du FH, et al. Auto Immun Highlights. 2017 Nov 16;8(1):12. doi: 10.1007/s13317-017-0100-y. Auto Immun Highlights. 2017. PMID: 29143151 Free PMC article.
These include the humanized versions: ocrelizumab, obinutuzumab, and veltuzumab, and the fully human, ofatumumab. We conducted a literature search of relevant randomized clinical trials in the PubMed database and ongoing trials in Clinicaltrials.gov. ...
These include the humanized versions: ocrelizumab, obinutuzumab, and veltuzumab, and the fully human, ofatumumab. We conducted a lite …
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH. Goldenberg DM, et al. Blood. 2009 Jan 29;113(5):1062-70. doi: 10.1182/blood-2008-07-168146. Epub 2008 Oct 21. Blood. 2009. PMID: 18941114 Free PMC article.
Mutation studies confirmed that the differentiation of the off-rate between veltuzumab and rituximab is related to the single amino acid change in CDR3-V(H). ...Low- and high-dose veltuzumab were significantly more effective in vivo than rituximab in 3 lymphoma mode …
Mutation studies confirmed that the differentiation of the off-rate between veltuzumab and rituximab is related to the single amino a …
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.
Liebman HA, Saleh MN, Bussel JB, Negrea OG, Horne H, Wegener WA, Goldenberg DM. Liebman HA, et al. Br J Haematol. 2013 Sep;162(5):693-701. doi: 10.1111/bjh.12448. Epub 2013 Jul 6. Br J Haematol. 2013. PMID: 23829485 Clinical Trial.
Eight patients, including 6 responders, developed anti-veltuzumab antibodies following treatment (human anti-veltuzumab antibody, 195%). Low-dose SC veltuzumab appears convenient, well-tolerated, and with promising clinical activity in relapsed ITP....
Eight patients, including 6 responders, developed anti-veltuzumab antibodies following treatment (human anti-veltuzumab antibo …
Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.
Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, Teoh N, Horne H, Wegener WA, Goldenberg DM. Negrea GO, et al. Haematologica. 2011 Apr;96(4):567-73. doi: 10.3324/haematol.2010.037390. Epub 2010 Dec 20. Haematologica. 2011. PMID: 21173095 Free PMC article. Clinical Trial.
DESIGN AND METHODS: A pilot study was undertaken to evaluate the potential for subcutaneous dosing with 2(nd) generation anti-CD20 antibody veltuzumab in patients with CD20(+) indolent non-Hodgkin's lymphoma. Patients with previously untreated or relapsed disease received …
DESIGN AND METHODS: A pilot study was undertaken to evaluate the potential for subcutaneous dosing with 2(nd) generation anti-CD20 antibody …
Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C, Castillo J. Milani C, et al. Curr Opin Mol Ther. 2009 Apr;11(2):200-7. Curr Opin Mol Ther. 2009. PMID: 19330725
Licensee Nycomed is developing veltuzumab for the potential treatment of rheumatoid arthritis and immune thrombocytopenic purpura (ITP). ...Currently there has been no evidence of an immune response to repeated administrations, and no serious adverse events related to v
Licensee Nycomed is developing veltuzumab for the potential treatment of rheumatoid arthritis and immune thrombocytopenic purpura (IT …
51 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page